CRL131 Phase 2 Studie bald mit Ergebnissen
www.cellectar.com/product-pipeline
- Cash 13 Mio. $
- MK 11 Mio. $ (zum 31.12.18)
- Verlust 15 Mio. $ (in 2018)
- pro Quartal ~4 Mio. $
- Watchlist
investor.cellectar.com/press-releases/...-year-ended-december
CLRB 2,16$
Beiträge: 23
Zugriffe: 9.988 / Heute: 4
Zugriffe: 9.988 / Heute: 4
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +82,31%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +64,89%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +40,67%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +38,52%
- FDA Fast Track Designation für CRL 131
- Phase 1 Studiendaten für CRL 131
www.contractpharma.com/contents/...t-track-for-clr-131-in-mm/
investor.cellectar.com/press-releases/...-rate-in-cohort-6-of
10 Mio. $ Offering
investor.cellectar.com/press-releases/...-0-million-financing
gestern nicht gekauft! Erst nen schönen Anstieg mit Rekordvolumen und dann eine KE. Ja, einfach mal den Allzeitchart bei den Amis anschauen!
www.nasdaq.com/de/symbol/clrb/real-time
www.nasdaq.com/de/symbol/clrb/real-time
für CLR 131
seekingalpha.com/news/...eed_news_all&utm_medium=referral
seekingalpha.com/news/...eed_news_all&utm_medium=referral
20 Mio. $ Offering
investor.cellectar.com/press-releases/...ricing-of-20-million
Heute steigen gefühlt alle Biotechs zweistellig.....nur Cellectar schmiert ab. Unschön.
Ich dachte die haben einen Geldspeicher wie Dagobert. Vermutlich nur Fakenews wie bei Donald.
Gruß Wilbär.
Das Geld gleicht dem Seewasser,jemehr man davon trinkt,umso durstiger wird man.
Offering
Verwunderlich das CLRB nicht stärker in Richtung des Angebotspreises vei 1,35$ fällt. Alles in allem sind das natürlich miese Konditionen. CLRB hatte gestern bei 2,77$ geschlossen und macht heute ein Offering zu 1,35$? 50% Discount?
seekingalpha.com/news/...ublic-offering-and-private-placement
Gelöschter Beitrag.
Einblenden
»
#16 
1/10 RS
investor.cellectar.com/press-releases/...-stock-consolidation
www.xm.com/research/markets/allNews/...d-cancer-drug-53643189
www.globenewswire.com/news-release/2023/...ch-Foundation.html
www.nasdaq.com/articles/...erapy-succeeds-in-late-stage-study
d1io3yog0oux5.cloudfront.net/...Top_line_Data_from_WM_315.pdf
Preliminary Third Quarter 2023 Financial Highlights
Cash and Cash Equivalents:As of September 30, 2023, the company had cash and
cash equivalents of $19.0 million, compared to $19.9 million as of December 31, 2022.
During the third quarter, the company entered into a securities purchase agreement
with certain institutional investors for a private placement financing that is expected to
result in gross proceeds of up to $102.9 million, based upon achievement of certain
milestones. Current cash includes an initial funding of $22.2 million from the
transaction, net of commissions and fees. The company believes its cash on hand is
adequate to fund budgeted operations into the second quarter of 2024.
Research and Development Expense: R&D expense for the three months ended
September 30, 2023 was approximately $7.3 million, compared to approximately $5.4
million for the three months ended September 30, 2022. The overall increase in
research and development expense was primarily a result of an increase in WM pivotal
trial patient enrollment and expansion of the central nervous system lymphoma cohort
of the company’s Phase 2a basket trial in blood-b
Preliminary Third Quarter 2023 Financial Highlights
Cash and Cash Equivalents:As of September 30, 2023, the company had cash and
cash equivalents of $19.0 million, compared to $19.9 million as of December 31, 2022.
During the third quarter, the company entered into a securities purchase agreement
with certain institutional investors for a private placement financing that is expected to
result in gross proceeds of up to $102.9 million, based upon achievement of certain
milestones. Current cash includes an initial funding of $22.2 million from the
transaction, net of commissions and fees. The company believes its cash on hand is
adequate to fund budgeted operations into the second quarter of 2024.
Research and Development Expense: R&D expense for the three months ended
September 30, 2023 was approximately $7.3 million, compared to approximately $5.4
million for the three months ended September 30, 2022. The overall increase in
research and development expense was primarily a result of an increase in WM pivotal
trial patient enrollment and expansion of the central nervous system lymphoma cohort
of the company’s Phase 2a basket trial in blood-b
bezüglich Cash und Cashreichweite die letzten sind (andere habe ich nicht gefunden)dann müsste demnächst eine KE anstehen.
Neueste Beiträge aus dem Cellectar New22 Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 22 | CLRB 2,16$ | Vassago | Balu4u | 08.01.24 15:00 |
